|6 Months Ended|
Jun. 30, 2023
Note 12 — Share-based compensation
The following table shows the total share-based compensation expense included in the unaudited consolidated statements of operations (in thousands):
The following table shows information about share options and options which have a nominal exercise price (similar to restricted stock units (RSUs)) granted:
The information above includes the impact of 29,654,742 options over ordinary shares and 5,501,602 options with a nominal exercise price granted on June 1, 2023, as replacement awards as part of the acquisition of TCR2 Therapeutics Inc., as explained further in Note 15. The number and fair value of replacement awards of the Company granted to TCR2 grantholders is provisional.
The entire disclosure for share-based payment arrangement.
Reference 1: http://www.xbrl.org/2003/role/exampleRef